Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanthanum carbonate in stage 3 chronic kidney disease: effects on intact FGF23
2009-016531-35Phase 2Completed
- Sponsor
- Takeda
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic kidney disease (CKD) comparing Lanthanum carbonate with Placebo (2 arms). Primary endpoint: Serum intact FGF23 level at week 12. Started Mar 2010; status: completed.
02
Drugs
lanthanum carbonate
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2009-016531-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016531-35.